Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis

Hepato-Gastroenterology

Volumn 53, Issue 70, 2006, Pages 608-612

  Talar Wojnarowska, Renata ^a,c   Gasiorowska, Anita ^a   Smolarz, Beata ^b   Romanowicz Makowska, Hanna ^b   Strzelczyk, Janusz ^a   Janiak, Adam ^a   Malecka Panas, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c Department of Digestive Tract Diseases ^*  (Poland)

Author keywords

Chronic pancreatitis; p53; Pancreatic adenocarcinoma

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; DNA ISOLATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PANCREATITIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREVALENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748654459     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feur EJ, Thun MJ, American Cancer Sociaty: Cancer statistics CA Cancer J Clin 2004; 54:8029.
2. Ebert M, Schandl L, Schmid RM: Differentiation of chronic pancreatitis from pancreatic cancer: recent advances in molecular diagnosis. Dig Dis 2001; 19:32-36.
3. Inoue S, Tezel E, Nakao A: Molecular diagnosis in pancreatic cancer. Hepatogastroenterology 2001; 48:933-938.
4. Hruban RH, Wilentz RE, Goggins M, et al: Pathology of incipient pancreatic cancer. Ann Oncol 1999; 10(Suppl 4):9-11.
5. Gerdes G, Ramaswamy A, Kersting M, et al: p16 INK4a alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. Surgery 2001; 129:490-497.
6. Andren-Sandberg A, Dervenis C, Lowenfels B: Etiologic links between chronic pancreatitis and pancreatic cancer. Scan J Gastroenterol 1997; 32:97-103.
7. Gold EO, Cameron JL: Chronic pancreatitis and pancreatic cancer. N Engl J Med 1993; 328:1485-1486.
8. Fernandez E, LaVecchia C, Porta M, et al: Pancreatitis and the risk of pancreatic cancer. Pancreas 1995; 11:185-189.
9. Chari ST, Mohan V, Pitchumoni CS, et al: Risk of pancreatic carcinoma in tropical calcifying pancreatitis: an epidemiological study. Pancreas 1994; 9:62-66.
10. Misra SP, Thorat VK, Vij JC, et al: Development of carcinoma in chronic calcific pancreatitis. Int J Pancreatol 1990; 6:307-312.
11. Ekbom A, McLaughin JK, Karlsson BM, et al: Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Ins 1994; 86:625-627.
12. Etemad B, Whitcomb DC: Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120:682-707.
13. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991; 351:453-456.
14. Dergham ST, Dugan MC, Kucway R, et al: Prevalence and clinical significance of combined K-ras mutation and p53 abberation in pancreatic adenocarcinoma. Int J Pancreatol 1997; 21(2):127-143.
15. Yamaguchi K, Chijiwa K, Noshiro H, et al: Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases. Hepatogastroenterology 1999; 46:2575-2581.
16. Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T, Sawabu N: Detection of mutation of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res 1999; 5:1147-1153.
17. Zhang SY, Ruggeri B, Agarwal P, et al: Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118:150-154.
18. Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH: Histological typing of tumours of the exocrine pancreas (2nd Edition), WHO International Histological Classification of tumours. Berlin: Springer-Verlag, 1996.
19. Terhune GP, Memoli VA, Longnecker DS: Evaluation of p53 mutation in pancreatic acinar cell carcinomas of humans and transgenic mice. Pancreas 1998; 16:6-12.
20. Talar-Wojnarowska R, Sasor A, Strzelczyk J, et al: Molecular basis of pancreatic cancer - selected issue. Gastrointestinal Oncology 2002; 4s:147-152.
21. Hermanova M, Lukas Z, Kroupova I, Kleibl Z, Novotny J, Nenutil R, Pazourkova M, Brazdil J, Kren L, Dite P: Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma. Neoplasma 2003; 50:319-325.
22. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731-1734.
23. Ruggeri BA, Huang L, Berger D, Chang H: Molecular pathology of primary and metastatic ductal pancreatic lesion. Cancer 1997; 79:700-716.
24. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee J, Abbruzzese JL: bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 1996; 2:2015-2022.
25. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S: Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995; 86:174-181.
26. Scarpa A, Moore PS, Rigaud G, Zamboni G: Genetic anomalies of pancreatic cancer. In: Dervenis CG, Bassi C (Eds.). Pancreatic tumors. Achievements and prospective. Stuttgart, New York: Georg Thieme Verlag, 2000; pp. 37-49.
27. Yamaguchi K, Chijiiwa K, Torato N, Kinoshita M, Tanaka M: Ki-ras codon 12 point and p53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer. Am J Gastroenterol 2000; 95:1939-1944.
28. Casey G, Yamanaka Y, Friess H: P53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Caner Lett 1993; 69:151-160.
29. Gansauge S, Schmid RM, Muller J, Adler G, Mattfeldt T, Beger HG: Genetic alterations in chronic pancreatitis: evidence for early occurence of p53 but not K-ras mutations. Br J Surg 1998; 85:337-340.
30. Luttges J, Diederichs A, Menke MA, Vogel I, Kremer B, Kloppel G: Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 2000; 88:2495-2504.
31. Maacke H, Kessler A, Schmiegel W, Roeder C, Vogel I, Deppert W, Kalthoff H: Overexpression of p53 protein during pancreatitis. Br J Cancer 1997; 75:1501-1504.
32. Yokoyama M, Yamanaka Y, Friess H, et al: p53 expression in human pancreatic cancer correlates with enhances biological aggressiveness. Anticancer Res 1994; 14:2477-2484.
33. Lu X, Xu T, Qian J, Wen X, Wu D: Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin Med 2002; 115:1632-1636.
34. Lohr M, Muller P, Mora J, Brinckmann B, Ostwald C, Farre A, Luis F, Adam U, Stubbe J, Plash F, Nizze H Hopt UT, Capella G, Liebe S: p53 and K-ras mutation in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc 2001; 53:734-743.
35. Wang Y, Yamaguchi Y, Watanabe H, Ohtsubo K, Motoo Y, Sawabu N: Detection of p53 gene mutations in the supernatant of pancreatic juice and plasma from patients with pancreatic adenocarcinoma. Pancreas 2004; 28:13-19.
36. Harada N, Gansauge S, Gansauge F, Ganse H, Shimoyama S, Imaizumi T, Mattfeld T, Schoenberg MH, Beger HG: Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21 in pancreatic cancer. Br J Cancer 1997; 76:299-305.
37. Campani D, Boggi U, Cecchetti D, Esposito I, Ceccarelli F, d'Antonio L, De Negri F, Mosca F, Bevilacqua G, Fornaciari G: p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas 1999; 19:26-32.
38. Kawesha A, Ghanwh P, Sandberg-Andren A, Ograed D, Skar R, Dawiskiba S, Evans JD, Cambell N, Lemoine N, Neoptolemos JP: K-ras oncogene subtype mutations are associated with survival but not expression of P53, P16, P21, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000; 89:469-474.
39. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB: Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 1999; 3:263-277.
40. Van Heek T, Rader AE, Offerhaus GJ, et al: K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002; 117(5):755-765.
41. Mu DQ, Wang GF, Peng SY: p53 protein expression and CA 19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis. Word J Gastroenterol 2003; 9:1815-1818.
42. Iwao T, Hanada K, Tsuchida A, Hirata M, Eguchi N, Kajiyama G: The establishment of preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 1998; 82:1487-1494.